Soluble Vascular Endothelial Growth Factor Receptor 1 in Tracheal Aspirate Fluid of Preterm Neonates at Birth May Be Predictive of Bronchopulmonary Dysplasia/Chronic Lung Disease

被引:36
作者
Hasan, Jamal [1 ,2 ]
Beharry, Kay D. [1 ]
Valencia, Arwin M. [2 ]
Strauss, Arthur [2 ]
Modanlou, Houchang D. [1 ]
机构
[1] Univ Calif Irvine, Dept Pediat, Div Neonatol Perinatal Med, Irvine, CA 92717 USA
[2] Miller Childrens Hosp, Dept Pediat, Div Neonatol Perinatal Med, Long Beach, CA USA
关键词
bronchopulmonary dysplasia; chronic lung disease; preterm infants; vascular endothelial growth factor; PREMATURE BABOONS; EXPRESSION; HYPOXIA; HYPERTENSION; INJURY; ROLES; FLT-1;
D O I
10.1542/peds.2008-1670
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE. We tested the hypothesis that soluble vascular endothelial growth factor receptors are involved in the development of bronchopulmonary dysplasia/chronic lung disease. PATIENTS AND METHODS. Neonates with a birth weight of <= 1500 g and/or <= 30 weeks' gestation, with respiratory failure, requiring O-2 and mechanical ventilation within 24 hours, were eligible. Tracheal aspirate fluid samples were collected from 65 neonates before surfactant and/or assisted mechanical ventilation (baseline), at 3 and 7 days after birth, and weekly thereafter until extubation. Samples were analyzed for total vascular endothelial growth factor, soluble vascular endothelial growth factor receptor 1 and 2 levels and compared in infants with bronchopulmonary dysplasia/chronic lung disease (n = 31) versus those with no bronchopulmonary dysplasia/chronic lung disease (n = 34). RESULTS. Mean gestational age and birth weight were lower in infants with bronchopulmonary dysplasia/chronic lung disease. At baseline, vascular endothelial growth factor levels in the tracheal aspirate fluid were significantly lower, whereas soluble vascular endothelial growth factor receptor 1 levels were higher in the bronchopulmonary dysplasia/chronic lung disease infants compared with infants with no bronchopulmonary dysplasia/chronic lung disease. Vascular endothelial growth factor levels progressively increased from baseline to 4 weeks in all of the infants developing bronchopulmonary dysplasia/chronic lung disease. Conversely, soluble vascular endothelial growth factor receptor 1 declined in both groups from baseline to 5 weeks of age. Similarly, soluble vascular endothelial growth factor receptor 2 declined from baseline to 5 weeks in the control infants, but there were significant increases at 3 and 4 weeks in infants developing bronchopulmonary dysplasia/chronic lung disease. CONCLUSIONS. We speculate that low vascular endothelial growth factor levels in tracheal aspirate fluid, concurrent with elevated soluble vascular endothelial growth factor receptor 1 levels on the first day of life, are biological markers for the development of bronchopulmonary dysplasia/chronic lung disease in very low birth weight infants requiring O-2 and assisted mechanical ventilation. Pediatrics 2009; 123: 1541-1547
引用
收藏
页码:1541 / 1547
页数:7
相关论文
共 29 条
[1]   Bronchopulmonary dysplasia - "A vascular hypothesis" [J].
Abman, SH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) :1755-1756
[2]   Vascular endothelial growth factor gene expression in human fetal lung in vitro [J].
Acarregui, MJ ;
Penisten, ST ;
Goss, KL ;
Ramirez, K ;
Snyder, JM .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1999, 20 (01) :14-23
[3]   Peptide growth factors in tracheal aspirates of mechanically ventilated preterm neonates [J].
Ambalavanan, N ;
Novak, ZE .
PEDIATRIC RESEARCH, 2003, 53 (02) :240-244
[4]   NEW BALLARD SCORE, EXPANDED TO INCLUDE EXTREMELY PREMATURE-INFANTS [J].
BALLARD, JL ;
KHOURY, JC ;
WEDIG, K ;
WANG, L ;
EILERSWALSMAN, BL ;
LIPP, R .
JOURNAL OF PEDIATRICS, 1991, 119 (03) :417-423
[5]   Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia [J].
Bhatt, AJ ;
Pryhuber, GS ;
Huyck, H ;
Watkins, RH ;
Metlay, LA ;
Maniscalco, WM .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (10) :1971-1980
[6]   A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation [J].
Clark, DE ;
Smith, SK ;
He, YL ;
Day, KA ;
Licence, DR ;
Corps, AN ;
Lammoglia, R ;
Charnock-Jones, DS .
BIOLOGY OF REPRODUCTION, 1998, 59 (06) :1540-1548
[7]  
Coalson JJ., 2000, LUNG BIOL HEALTH DIS, P85
[8]   The role of vascular growth factors in hyperoxia-induced injury to the developing lung [J].
D'Angio, CT ;
Maniscalco, WM .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 :D1609-D1623
[9]   Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth, factor receptor-2 levels as a surrogate biomarker for tumor growth [J].
Ebos, John M. L. ;
Lee, Christina R. ;
Bogdanovic, Elena ;
Alami, Jennifer ;
Van Slyke, Paul ;
Francia, Giulio ;
Xu, Ping ;
Mutsaers, Anthony J. ;
Dumont, Daniel J. ;
Kerbel, Robert S. .
CANCER RESEARCH, 2008, 68 (02) :521-529
[10]   Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia [J].
Ehrenkranz, RA ;
Walsh, MC ;
Vohr, BR ;
Jobe, AH ;
Wright, LL ;
Fanaroff, AA ;
Wrage, LA ;
Poole, K .
PEDIATRICS, 2005, 116 (06) :1353-1360